The role of androgens in metabolism, obesity, and diabetes in males and females

Obesity

Volumn 23, Issue 4, 2015, Pages 713-719

  Navarro, Guadalupe ^a   Allard, Camille ^b   Xu, Weiwei ^b   Mauvais Jarvis, Franck ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTRADIOL; HEMOGLOBIN A1C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANDROGEN DEFICIENCY; CENTRAL NERVOUS SYSTEM; DISEASE PREDISPOSITION; ENERGY EXPENDITURE; ENERGY METABOLISM; FAT MASS; GENDER; GENE FUNCTION; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERANDROGENISM; HYPERGLYCEMIA; HYPOGONADISM; HYPOTHALAMUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID HOMEOSTASIS; LIPID STORAGE; LIVER; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE; ANIMAL; FEMALE; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; PHYSIOLOGY; SEX DIFFERENCE;

RODENTIA;

ADIPOSE TISSUE; ANDROGENS; ANIMALS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC DISEASES; METABOLIC SYNDROME X; MUSCLE, SKELETAL; OBESITY; RECEPTORS, ANDROGEN; SEX FACTORS;

EID: 84925881104     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21033     Document Type: Review

References (80)

1. Zitzmann M,. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009; 5: 673-681.
2. Mauvais-Jarvis F,. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab 2011; 22: 24-33.
3. Keating NL, O'Malley A, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2012; 104: 1518-1523.
4. Achard C, Thiers J,. Le virilisme pilaire et son association a l'insuffisance glycolytique (diabete des femmes a barbe). Bull Acad Natl Med Paris 1921; 86: 51-55.
5. Stein J, Leventhal ML,. Amenorreha associated with bilateral polycystic ovaries. Am J obstet Gynecol 1935; 20: 181-187.
6. Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 2009; 52: 3597-3617.
7. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2011; 34: 528-540.
8. Ding EL, Song Y, Malik VS, Liu S,. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295: 1288-1299.
9. Grossmann M,. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metabolism 2011; 96: 2341-2353.
10. Grossmann M, Zajac JD,. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol 2011; 74: 289-293.
11. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
12. Keating NL, O'Malley A, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2012; 104: 1518-1523.
13. Inaba M, Otani Y, Nishimura K, Takaha N, Okuyama A, Koga M, et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 2005; 54: 55-59.
14. Ho CH, Yu HJ, Wang CY, Jaw FS, Hsieh JT, Liao WC, et al. Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PloS One 2013; 8: e74173.
15. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS,. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-588.
16. Khaw KT, Barrett-Connor E,. Lower endogenous androgens predict central adiposity in men. Annals Epidemiol 1992; 2: 675-682.
17. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28: 1636-1642.
18. Zitzmann M, Faber S, Nieschlag E,. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metabolism 2006; 91: 4335-4343.
19. Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, et al. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 2006; 29: 1591-1598.
20. Moverare-Skrtic S, Venken K, Andersson N, Lindberg MK, Svensson J, Swanson C, et al. Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity (Silver Spring) 2006; 14: 662-672.
21. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. New England J Med 2013; 369: 1011-1022.
22. Mauvais-Jarvis F, Clegg DJ, Hevener AL,. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 2013; 34: 309-338.
23. Zitzmann M, Gromoll J, von Eckardstein A, Nieschlag E,. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 2003; 46: 31-39.
24. Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, et al. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 2005; 54: 1000-1008.
25. Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C,. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes 2005; 54: 1717-1725.
26. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E,. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clinical Endocrinol 2004; 60: 500-507.
27. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-2741.
28. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S,. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 5081-5088.
29. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006; 147: 141-154.
30. Gentile MA, Nantermet PV, Vogel RL, Phillips R, Holder D, Hodor P, et al. Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of {beta}-catenin. J Mol Endocrinol 2010; 44: 55-73.
31. Fernando SM, Rao P, Niel L, Chatterjee D, Stagljar M, Monks DA,. Myocyte androgen receptors increase metabolic rate and improve body composition by reducing fat mass. Endocrinology 2010; 151: 3125-3132.
32. Yu IC, Lin HY, Liu NC, Wang RS, Sparks JD, Yeh S, et al. Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue. Endocrinology 2008; 149: 2361-2368.
33. Ophoff J, Van Proeyen K, Callewaert F, De Gendt K, De Bock K, Vanden Bosch A, et al. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology 2009; 150: 3558-3566.
34. Holmang A, Bjorntorp P,. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 1992; 146: 505-510.
35. Haren MT, Siddiqui AM, Armbrecht HJ, Kevorkian RT, Kim MJ, Haas MJ, et al. Testosterone modulates gene expression pathways regulating nutrient accumulation, glucose metabolism and protein turnover in mouse skeletal muscle. Int J Androl 2011; 34: 55-68.
36. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
37. Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 2008; 47: 1924-1935.
38. Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N, et al. Loss of 5alpha-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology 2013; 154: 4536-4547.
39. Livingstone DE, Barat P, Di Rollo EM, Rees GA, Weldin BA, Rog-Zielinska EA, et al. 5alpha-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis and liver fibrosis in rodents. Diabetes 2014. pii: DB-140249. [Epub ahead of print]
40. Volzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl 2010; 33: 45-53.
41. Fan W, Yanase T, Nishi Y, Chiba S, Okabe T, Nomura M, et al. Functional potentiation of leptin-signal transducer and activator of transcription 3 signaling by the androgen receptor. Endocrinology 2008; 149: 6028-6036.
42. Yu IC, Lin HY, Liu NC, Sparks JD, Yeh S, Fang LY, et al. Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-kappaB-mediated PTP1B expression. Diabetes 2013; 62: 411-423.
43. Maclaren NK, Neufeld M, McLaughlin JV, Taylor G,. Androgen sensitization of streptozotocin-induced diabetes in mice. Diabetes 1980; 29: 710-716.
44. Paik SG, Michelis MA, Kim YT, Shin S,. Induction of insulin-dependent diabetes by streptozotocin. Inhibition by estrogens and potentiation by androgens. Diabetes 1982; 31: 724-729.
45. Morimoto S, Mendoza-Rodriguez CA, Hiriart M, Larrieta ME, Vital P, Cerbon MA,. Protective effect of testosterone on early apoptotic damage induced by streptozotocin in rat pancreas. J Endocrinol 2005; 187: 217-224.
46. Palomar-Morales M, Morimoto S, Mendoza-Rodriguez CA, Cerbon MA,. The protective effect of testosterone on streptozotocin-induced apoptosis in beta cells is sex specific. Pancreas 2010; 39: 193-200.
47. Morimoto S CM, Alvarez-Alvarez A, Romero-Navarro G, Díaz-Sánchez V,. Insulin gene expression pattern in rat pancreas during the estrous cyle. Life Sci 2001; 68: 2979-2985.
48. Navarro G, Mauvais-Jarvis F,. The role of the Androgen Receptor in beta-cell function in male mice. Diabetes 2013; 62: A571.
49. Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S,. Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 2003; 300: 167-171.
50. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C, Bjorntorp P,. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 1991; 40: 123-128.
51. Larsson H, Ahren B,. Androgen activity as a risk factor for impaired glucose tolerance in postmenopausal women. Diabetes Care 1996; 19: 1399-1403.
52. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, Paolisso G, et al. Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study. Am J Physiol Endocrinol Metabolism 2007; 292: E353-E358.
53. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P,. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405-411.
54. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL,. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55-60.
55. Tok EC, Ertunc D, Evruke C, Dilek S,. The androgenic profile of women with non-insulin-dependent diabetes mellitus. J Reproductive Med 2004; 49: 746-752.
56. Page-Wilson G, Goulart AC, Rexrode KM,. Interrelation between sex hormones and plasma sex hormone-binding globulin and hemoglobin A1c in healthy postmenopausal women. Metabolic Syndrome Related Disord 2009; 7: 249-254.
57. Dreaden EC, Gryder BE, Austin LA, Tene Defo BA, Hayden SC, Pi M, et al. Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjugate Chem 2012; 23: 1507-1512.
58. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S,. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 2007; 50: 2076-2084.
59. Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA,. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metabolism 1998; 83: 4420-4425.
60. Shamma FN, Rossi G, HajHassan L, Penzias AS, Connoly-Diamond M, Jones E, et al. The effect of Norplant on glucose metabolism under hyperglycemic hyperinsulinemic conditions. Fertility Sterility 1995; 63: 767-772.
61. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ,. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metabolism 1994; 79: 265-271.
62. Holmang A, Larsson BM, Brzezinska Z, Bjorntorp P,. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 1992; 262: E851-E855.
63. Holmang A, Svedberg J, Jennische E, Bjorntorp P,. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 1990; 259: E555-E560.
64. Zulian E, Sartorato P, Benedini S, Baro G, Armanini D, Mantero F, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005; 28: 49-53.
65. Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metabolism 2006; 91: 3970-3980.
66. Corbould A,. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome? Diabetes Metab Res Rev 2008; 24: 520-532.
67. Bouchard C, Despres JP, Mauriege P,. Genetic and nongenetic determinants of regional fat distribution. Endocr Rev 1993; 14: 72-93.
68. Bjorntorp P,. Abdominal fat distribution and disease: an overview of epidemiological data. Ann Med 1992; 24: 15-18.
69. Evans DJ, Barth JH, Burke CW,. Body fat topography in women with androgen excess. Int J Obes 1988; 12: 157-162.
70. Montes-Nieto R, Insenser M, Martinez-Garcia MA, Escobar-Morreale HF,. A nontargeted proteomic study of the influence of androgen excess on human visceral and subcutaneous adipose tissue proteomes. J Clin Endocrinol Metabolism 2013; 98: E576-E585.
71. Gambineri A, Fanelli F, Tomassoni F, Munarini A, Pagotto U, Andrew R, et al. Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls. Eur J Endocrinol 2014; 171: 47-57.
72. Nohara K, Laque A, Allard C, Munzberg H, Mauvais-Jarvis F,. Central mechanisms of adiposity in adult female mice with androgen excess. Obesity (Silver Spring) 2014; 22: 1477-1484.
73. O'Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metabolism 1993; 76: 1241-1247.
74. Dunaif A, Finegood DT,. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metabolism 1996; 81: 942-947.
75. Holte J, Bergh T, Berne C, Berglund L, Lithell H,. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metabolism 1994; 78: 1052-1058.
76. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG,. Beta-cell function: a key pathological determinant in polycystic ovary syndrome. J Clin Endocrinol Metabolism 2005; 90: 310-315.
77. Liu S, Navarro G, Mauvais-Jarvis F,. Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PloS One 2010; 5: e11302.
78. Gonzalez F, Rote NS, Minium J, Kirwan JP,. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metabolism 2006; 91: 1508-1512.
79. Roland AV, Nunemaker CS, Keller SR, Moenter SM,. Prenatal androgen exposure programs metabolic dysfunction in female mice. J Endocrinol 2010; 207: 213-223.
80. Navarro G, Suhuan Liu P, De Gendt K, Verhoeven G, Mauvais-Jarvis F,. Importance of the beta-cell androgen receptor in type 2 diabetes. Endocr Rev 2011; 32: OR23-OR22.